Inhibiteur enzyme And NotE. Brouillet
List of bibliographic references
Number of relevant bibliographic references: 26.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000588 | Serge Guerreiro [France] ; Aurélie Ponceau [France] ; Damien Toulorge [France] ; Elodie Martin [France] ; Daniel Alvarez-Fischer [France] ; Etienne C. Hirsch [France] ; Patrick P. Michel [France] | Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization |
| 000795 | Margarete Zanardo Gomes [Brésil] ; Rita Raisman-Vozari [France] ; Elaine A. Del Bel [Brésil] | A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway |
| 000880 | Alexandre Kreisler [France] ; Patrick Gele [France] ; Jean-Francois Wiart [France] ; Michel Lhermitte [France] ; Alain Destke [France] ; Régis Bordet [France] | Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease : Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not |
| 000B11 | Marina Mapelli [Italie] ; Lucia Massimiliano [Italie] ; Claudia Crovace [Italie, États-Unis] ; Markus A. Seeliger [États-Unis] ; Li-Huei Tsai [France] ; Laurent Meijer [France] ; Andrea Musacchio [Italie] | Mechanism of CDK5/p25 binding by CDK inhibitors |
| 000C60 | N. Hamaue [Japon] ; M. Minami [Japon] ; M. Terado [Japon] ; M. Hirafuji [Japon] ; T. Endo [Japon] ; M. Machida [Japon] ; T. Hiroshige [Japon] ; A. Ogata [Japon] ; K. Tashiro [Japon] ; H. Saito [Japon] ; S. H. Parvez [France] | Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus |
| 000D47 | J. G. Delcros [France] ; M. Baudy Floc'H [France] ; C. Prigent [France] ; Y. Arlot-Bonnemains [France] | Proteasome inhibitors as therapeutic agents: Current and future strategies |
| 000D70 | Olivier Rascol [France] ; Pierre Payoux [France, Portugal] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France] | Limitations of current Parkinson's disease therapy. Discussion |
| 000E14 | Parkinson et mouvements anormaux | |
| 000E28 | A. Destee [France] ; R. Bordet [France] | Stimulation dopaminergique continue, stimulation dopaminergique pulsatile |
| 000F10 | P. Volders [Belgique] ; J. Van Hove [Belgique] ; R. J. U. Lories [Belgique] ; Ph. Vandekerckhove [Belgique] ; G. Matthijs [Belgique] ; R. De Vos [Belgique] ; M. T. Vanier [France] ; M. F. Vincent [Belgique] ; R. Westhovens [Belgique] ; F. P. Luyten [Belgique] | Niemann-Pick disease type B: An unusual clinical presentation with multiple vertebral fractures |
| 000F34 | A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France] | Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease |
| 000F42 | J. S. Schneider [États-Unis] ; M. Giardiniere [États-Unis] ; P. Morain [France] | Effects of the prolyl endopeptidase inhibitor S17092 on cognitive deficits in chronic low dose MPTP-treated monkeys |
| 000F62 | Marion Blin [France] ; Wim E. Crusio [États-Unis] ; Tobias Hevor [France] ; Jean-Francois Cloix [France] | Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice |
| 001063 | Stéphanie Barc [France] ; Guylène Page [France] ; Laurence Barrier [France] ; Alain Piriou [France] ; Bernard Fauconneau [France] | Impairment of the neuronal dopamine transporter activity in MPP+-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors |
| 001078 | S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France] | Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease |
| 001111 | M. H. Marion [Royaume-Uni] | Traitement médicamenteux des complications motrices à un stade évolué de la maladie de Parkinson |
| 001121 | P. Damier [France] | Quelles stratégies thérapeutiques sont à conseiller à la phase initiale de la maladie ? Les autres traitements |
| 001175 | A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France] | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation |
| 001231 | C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] | Continuous dopamine-receptor stimulation in early Parkinson's disease |
| 001342 | Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients | |
| 001422 | O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 001582 | F. Coudore [France] ; F. Durif [France] ; E. Duroux [France] ; A. Eschalier [France] ; J. Fialip [France] | Effect of tolcapone on plasma and striatal apomorphine disposition in rats |
| 001705 | L. Lebreton [France] ; O. Curet [France] ; S. Gueddari [France] ; FATHI MAZOUZ [France] ; S. Bernard [France] ; C. Burstein [France] ; R. Milcent [France] | Selective and potent monoamine oxidase type B inhibitors : 2-substituted 5-aryltetrazole derivatives |
| 001724 | F. N. Bolkenius [France] ; D. Monard | Inactivation of protease nexin-1 by xanthine oxidase-derived free radicals |
| 001741 | P. Limousin [France] ; P. Pollak [France] ; J. P. Pfeffen ; C. L. Tournier-Gervason [France] ; R. Dubuis ; J. E. Perret [France] | Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease |
| 001A65 | J. L. Montastruc | A propos de l'étude DATATOP : déprényl® (sélégiline) dans le traitement de la maladie de Parkinson |
| This area was generated with Dilib version V0.6.29. |  |